Contineum Therapeutics' PIPE-307 Fails Phase 2 Multiple Sclerosis Trial
核心洞察
Contineum Therapeutics' lead experimental drug PIPE-307 failed to meet primary and secondary endpoints in a mid-stage clinical trial for relapsing-remitting multiple sclerosis.
The study tested two different doses of PIPE-307 against placebo, with neither dose showing significant impact on the primary vision test endpoint despite acceptable safety profiles.
Company shares fell more than 12% in after-hours trading following the announcement, with the stock hovering around $12.20 per share.
Contineum Therapeutics disclosed Thursday that its most advanced experimental drug PIPE-307 has failed as a multiple sclerosis treatment in a mid-stage clinical trial, marking a significant setback for the San Diego-based biotechnology company.
Trial Results and Primary Endpoint Failure
The study compared two different doses of PIPE-307 to placebo in patients with relapsing-remitting MS, the most common form of the disease. While both doses demonstrated "acceptable" safety and tolerability profiles, they failed to show significant impact on the trial's primary endpoint—a vision test requiring participants to read faint letters. Blurry or impaired eyesight frequently represents one of the first noticeable symptoms of multiple sclerosis.
PIPE-307 also missed all secondary endpoints in the trial. According to the company's statement, Contineum will continue analyzing data from "exploratory" study objectives and plans to present complete results at an upcoming medical meeting while publishing findings in a peer-reviewed journal.
Market Response and Company Background
Following the announcement, Contineum shares dropped more than 12% in after-hours trading Thursday, settling around $12.20 per share. The biotech has struggled since its 2024 public debut, with shares consistently trading below their $16 initial price amid a broader downturn in biotech stocks.
Originally founded in 2017 as Pipeline Therapeutics, Contineum has raised substantial funding through multiple rounds. The company secured $30 million in a Series B round in late 2019, led by founding investor Versant Ventures (搜索), followed by an $80 million Series C round. The company completed its public offering in 2024, raising $110 million.
Drug Mechanism and Pipeline
PIPE-307 is designed to inhibit "M1," a member of a protein family that regulates the nervous system and potentially controls immune system components. In multiple sclerosis, the immune system mistakenly attacks protective coatings surrounding nerve cells, causing various sensory, mobility, and cognitive complications. Research published in Molecular Pharmacology this year describes how M1 may impede the body's ability to repair these protective coatings.
The company maintains a second drug in human testing: PIPE-791, currently in early-stage trials for chronic pain, progressive MS, and idiopathic pulmonary fibrosis (IPF). This compound works by blocking "LPAR1 (搜索)," a multifunctional receptor protein. Several other developers, including Bristol Myers Squibb (搜索), are pursuing similar therapeutic approaches.
Analyst Perspective and Future Outlook
"While we are disappointed by the result, we had always viewed the study as risky," wrote Myles Minter, an analyst at William Blair (搜索), in a client note. Minter considers PIPE-791 responsible for the "lion's share" of Contineum's value, describing its mechanism for treating IPF as an "exciting" approach.
Researchers are also investigating PIPE-307's potential in treating major depression. Minter noted he sees "little read-through" from the failed MS trial to the ongoing depression study, though he acknowledges the latter remains risky. The William Blair (搜索) team estimates a 35% probability of success for the depression indication.
Chief Medical Officer and head of development Timothy Watkins stated that the company remains "committed" to finding new therapies for inflammatory and fibrotic diseases despite the setback.